Last reviewed 2026-05-14 · How we verify

epinastine 0.1% with taste masking agent

Merck Sharp & Dohme LLC · Phase 2 active Small molecule

epinastine 0.1% with taste masking agent is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 2 development.

At a glance

Generic name	epinastine 0.1% with taste masking agent
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

epinastine 0.1% with taste masking agent CI brief — competitive landscape report
epinastine 0.1% with taste masking agent updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI

Frequently asked questions about epinastine 0.1% with taste masking agent

What is epinastine 0.1% with taste masking agent?

epinastine 0.1% with taste masking agent is a Small molecule drug developed by Merck Sharp & Dohme LLC.

Who makes epinastine 0.1% with taste masking agent?

epinastine 0.1% with taste masking agent is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

What development phase is epinastine 0.1% with taste masking agent in?

epinastine 0.1% with taste masking agent is in Phase 2.

Manufacturer: Merck Sharp & Dohme LLC — full pipeline